Renaissance Capital logo

Telix Pharmaceuticals Withdrawn, Nasdaq: TLX

Commercial-stage Australian biotech developing therapeutic and diagnostic radiopharmaceuticals.

Industry: Health Care

Latest Trade: ()

First Day Return:

Return from IPO:

Industry: Health Care

We are a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. Our mission is to be the global leader in radiopharmaceuticals by combining therapeutic and diagnostic modalities for the benefit of patients, an innovative precision medicine concept generally referred to as “theranostics”. We have an extensive pipeline of theranostic radiopharmaceutical product candidates with a focus in urologic oncology (prostate and kidney), neuro-oncology (glioma), musculoskeletal oncology (sarcoma) and bone marrow conditioning. Our theranostic approach is intended to use imaging and therapy together to “see and treat” cancer and rare diseases, to both better inform treatment decisions and deliver personalized therapy for patients. Our products are designed to deliver targeted radiation to cancer cells with precision via a systemic radioactive infusion in order to treat tumors regardless of where they are in the body. This targeted radiation uses a radioactive isotope as a payload, which is attached to a targeting agent (such as a small molecule or antibody) with an affinity for targeted biomarkers on the surface of cancerous or diseased cells. Depending on the choice of radioisotope payload, we can deliver the payload as an imaging agent or as a therapy. The specificity of the targeting agent is designed to concentrate radiation at the tumor sites and to limit off-target tissue exposure.
more less
IPO Data
IPO File Date 05/17/2024
Offer Price
Price Range $11.87 - $11.87
Offer Shares (mm) 17.0
Deal Size ($mm) $202
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date
Offer Price
Price Range $11.87 - $11.87
Offer Shares (mm) 17.0
Deal Size ($mm) $202
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
Jefferies
Morgan Stanley
more
Company Data
Headquarters North Melbourne, Australia
Founded 2017
Employees at IPO 431
Website www.telixpharma.com

Telix Pharmaceuticals (TLX) Performance